Development of generics using ‘clopidogrel,’ an antiplatelet drug, is regaining momentum. A company that already owned a clopidogrel generic has released a new dose product in 16 years.

And the generic companies have been showing positive responses after the effect of clopidogrel was reilluminated in a study on stent-inserted patients, raising expectations that competition in clopidogrel will intensify again in the future.

According to industry sources on the 13th, 13 bioequivalence tests on clopidogrel were approved just this year, 9 of which were approved after May this year. Compared to the average of 4.3 cases that were approved in the 3 years from 2018 to 2020, the number of tests